KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Notes Payables (2024 - 2025)

Esperion Therapeutics (ESPR) has disclosed Notes Payables for 2 consecutive years, with $54.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Notes Payables changed N/A year-over-year to $54.9 million, compared with a TTM value of $54.9 million through Sep 2025, changed N/A, and an annual FY2024 reading of $54.6 million, changed N/A over the prior year.
  • Notes Payables was $54.9 million for Q3 2025 at Esperion Therapeutics, roughly flat from $54.8 million in the prior quarter.
  • Across five years, Notes Payables topped out at $54.9 million in Q3 2025 and bottomed at $54.6 million in Q4 2024.